Technology | EP Mapping and Imaging Systems | January 19, 2018

Abbott Announces European Launch of Advisor HD Grid Mapping Catheter, Sensor Enabled

New device facilitates rapid, complex arrhythmia diagnosis and enables physicians to map any chamber of the heart to best determine ablation strategy and optimize patient care

Abbott Announces European Launch of Advisor HD Grid Mapping Catheter, Sensor Enabled

January 19, 2018 — Abbott last week announced CE Mark approval for the company's new Advisor HD Grid Mapping Catheter, Sensor Enabled, a product designed to advance cardiac mapping during cardiac ablation to treat patients with complex cardiac arrhythmias. With the European launch of this latest addition to Abbott’s electrophysiology portfolio, the company is offering physicians a mapping catheter with what it calls a first-of-its-kind grid configuration of electrodes for improved data collection that supports the creation of high-density mapping of cardiac tissue to support optimal treatment for patients.

For patients battling complex arrhythmias, physicians may use cardiac ablation therapy to create tiny scars or lesions on the heart to stop erratic electrical signals. Yet to ensure the best outcomes for their patients, physicians first need to identify which areas of the heart are responsible for those signals.  Mapping catheters are critical to providing this insight.

Indicated for use in any chamber of the heart, the Advisor HD Grid mapping catheter is designed to combat challenges sometimes associated with traditional mapping catheters.

Linear or circular mapping catheters may experience signal disruptions as the orientation of the catheter changes. The Advisor HD Grid mapping catheter is intended to help physicians avoid signal loss by allowing for data to be captured horizontally and vertically along a new electrode grid configuration with 16 sensors. As a result, the catheter utilizes high-density mapping to create detailed and anatomically accurate 3-D models of the heart.

Abbott's Advisor HD Grid mapping catheter enables physicians to collect data simultaneously along the catheter’s grid pattern to help optimize treatment decisions. Combined with the EnSite Precision Cardiac Mapping System, the data captured by the catheter is used to create a highly detailed map highlighting the differences between healthy tissue and tissue responsible for a patient's cardiac arrhythmias, such as atrial fibrillation. Such detail can make an important impact on a physician's ablation strategy and approach to patient care.

As an added benefit for physicians, by designing the Advisor HD Grid mapping catheter as Sensor Enabled, Abbott has allowed the catheter to capture data in two ways – through impedance and magnetic collection, improving how data is collected and providing physicians additional flexibility when pairing the catheter with the EnSite Precision Cardiac Mapping System.

For more information: www.sjmglobal.com

 

Related Content

Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init